US · Healthcare · Biotechnology
EPS came in at -4.88 against a street estimate of -4.61 — a miss of 5.9%.
Analysts rate Attovia Therapeutics, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $42.20.
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ATTOVIA THERAPEUTICS, INC. — 10-Q SUMMARY FOR Q2 2026 HEADLINE NUMBERS • Cash position: $32.8 million in cash and cash equivalents as of June 30, 20 | 2026-09-02 |
| Results announced · Q3 2026 ATTOVIA THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • IPO Gross Proceeds: $332.4 million upsized offering completed in August 2026; net | 2026-09-02 |
| Charter / bylaws change · Q3 2026 ATTOVIA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company completed initial public offering (IPO) on August 6, 2026 • Trading symbol: ATTO | 2026-08-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Attovia Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.